A collaboration between scientists at the Institute of Molecular and Clinical Ophthalmology Basel (IOB) and Beam Therapeutics has resulted in a new base editing therapy for Stargardt disease, the most ...

Austin, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Base Editing Market Growth Analysis: As per SNS Insider, the Base Editing Market size was estimated to be USD 254.16 million in 2025 and is expected to ...

X-linked chronic granulomatous disease (X-CGD) is a rare genetic disorder characterized by high susceptibility to infections that results from genetic mutations in the cytochrome b-245 beta chain ...

Mayo Clinic researchers have developed a promising gene-editing therapy that directly corrects a genetic mutation responsible for autosomal dominant polycystic kidney disease (ADPKD), the most common ...

Forbes contributors publish independent expert analyses and insights. Juergen Eckhardt leads Bayer’s impact investment unit, Leaps by Bayer. Dr. David Liu, pictured with former lab members Holly Rees ...

In a step toward treating mitochondrial diseases, researchers in the Netherlands have successfully edited harmful mutations in mitochondrial DNA using a genetic tool known as a base editor. The ...

Scientists and physicians can better assess precision genome editing technology using a new method made public today by St. Jude Children's Research Hospital. Significant amounts of time and resources ...

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns about ...

You may have seen it in the news recently: a baby in Pennsylvania with a rare genetic disorder was healed with a personalized treatment that repaired his specific genetic mutation. The treatment was ...

(MENAFN- GlobeNewsWire - Nasdaq) Advancements in genome editing technologies the growing emphasis on safe and accurate gene correction, and strong biotechnology R&D investment drive the base editing ...